Examkin

Soru

Zorluk: ZorPharmacokinetic and Pharmacodynamic Principles

An emergency department physician is evaluating a 72-year-old male who presents with acute palpitations and shortness of breath. His medical history is notable for ischemic cardiomyopathy (left ventricular ejection fraction of 25%25\%) and end-stage renal disease managed with thrice-weekly hemodialysis. His routine outpatient medications include carvedilol, lisinopril, and atorvastatin. An electrocardiogram confirms atrial fibrillation with a rapid ventricular response. The patient is transferred to the cardiac intensive care unit and receives a loading dose of intravenous amiodarone, which does not adequately reduce his heart rate. The critical care team decides to initiate intravenous digoxin. Compared to a patient of identical body weight with normal renal function who is not taking amiodarone, how should the initial digoxin dosing strategy be modified for this patient?

  1. Decrease both the loading dose and the maintenance doseCevap
  2. B
    Administer a standard loading dose and decrease the maintenance dose
  3. C
    Increase the loading dose and decrease the maintenance dose
  4. D
    Decrease the loading dose and administer a standard maintenance dose
  5. E
    Administer a standard loading dose and a standard maintenance dose

Cevap

Decrease both the loading dose and the maintenance dose
The correct strategy involves decreasing both the loading dose and the maintenance dose. The loading dose is calculated based on the drug's apparent volume of distribution (VdV_d). Digoxin binds extensively to skeletal muscle; however, in patients with end-stage renal disease, endogenous uremic substances compete for these tissue binding sites, or the affinity of the receptors decreases. This effectively reduces the VdV_d of digoxin from approximately 7 L/kg7 \text{ L/kg} to 4−5 L/kg4-5 \text{ L/kg}. To achieve the same target peak serum concentration without causing toxicity, the loading dose must be decreased. Furthermore, the maintenance dose of a drug is directly proportional to its clearance. Digoxin is primarily eliminated unchanged by the kidneys, so renal failure drastically reduces its clearance. Additionally, the patient was given amiodarone, which is a potent inhibitor of P-glycoprotein, an efflux transporter responsible for the secretion of digoxin. The concurrent use of amiodarone further decreases digoxin clearance, mandating a significant reduction in the maintenance dose.

Adım Adım Çözüm

1
Analyze the patient's organ function to determine its effect on the drug's volume of distribution (VdV_d).
The patient has end-stage renal disease (ESRD), which impairs the binding of digoxin to skeletal muscle, leading to a decreased VdV_d (from ≈7 L/kg\approx 7 \text{ L/kg} to ≈4−5 L/kg\approx 4-5 \text{ L/kg}).
The loading dose of a medication is directly proportional to its VdV_d. A decreased VdV_d necessitates a proportionally lower loading dose.
2
Evaluate the impact of organ dysfunction and drug-drug interactions on the drug's clearance.
Renal failure significantly impairs digoxin excretion. Additionally, amiodarone is a potent P-glycoprotein inhibitor, which further reduces digoxin clearance by approximately 50%50\%.
The maintenance dose of a drug is directly proportional to its clearance. Severely reduced clearance requires a lower maintenance dose.
3
Synthesize these pharmacokinetic changes to formulate the final dosing strategy.
Both the loading dose and maintenance dose must be decreased compared to a patient with normal organ function not receiving amiodarone.
Decreasing the loading dose prevents initial toxicity from a contracted VdV_d, and decreasing the maintenance dose prevents delayed toxicity from impaired clearance.

Anahtar Kavram

In end-stage renal disease, the volume of distribution of digoxin decreases due to reduced tissue binding, mandating a lower loading dose. Its clearance is also substantially decreased by renal impairment and P-glycoprotein inhibitors (like amiodarone), requiring a lower maintenance dose.
Bu soruyu puanla

Konular

Pharmacokinetic and Pharmacodynamic Principles

Bu konudan daha fazla soru